{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:24:03Z","timestamp":1787009043718,"version":"build-2736575974"},"reference-count":29,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T00:00:00Z","timestamp":1572998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Infectious Disease Unit"},{"name":"Wolfson Medical Center"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>We studied the performance of aminoglycosides in treating bloodstream infections (BSIs) of urinary source caused by ESBL-producing Enterobacteriaceae (ESBL-EB).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In a retrospective study of 193 patients with a clinical diagnosis of urinary tract infection, pyelonephritis or urosepsis and blood and urine cultures positive for ESBL-EB, patients were grouped according to whether they were treated with an aminoglycoside, a carbapenem or piperacillin\/tazobactam. Multivariate analysis was used to define risk factors for mortality with inverse probability of treatment weighting used to minimize confounding. The primary efficacy outcome was 30\u2009day mortality. The primary safety outcome was acute kidney injury (AKI) at 14\u2009days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Mean age was 79.3\u2009years. Dementia, chronic kidney disease and the presence of a urinary catheter were common. Thirty-two (16.6%) patients died and risk factors for mortality included age, high Charlson score, presentation with severe sepsis\/septic shock and infection with bacteria other than Escherichia coli. Aminoglycosides were non-inferior compared with other antibiotics regarding 30\u2009day mortality [13.0% versus 21.2%, respectively; adjusted risk difference=10.29% (\u22120.82% to 21.41%)], but did not reach non-inferiority for bacteriuria recurrence [48.9% versus 44.7%, respectively; adjusted risk difference=\u22128.72% (\u221230.87% to 13.43%)]. AKI developed at a similar rate in both treatment groups: 12.0% versus 10.6%, respectively [OR=1.14 (0.46\u20132.81)]. Aminoglycosides were more efficacious in E. coli infections compared with other ESBL-EB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We demonstrated the efficacy and safety of aminoglycosides in treating BSI of urinary source caused by ESBL-EB. This carbapenem-sparing approach can assist in avoiding excessive carbapenem use without compromising outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkz457","type":"journal-article","created":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T16:55:38Z","timestamp":1571158538000},"source":"Crossref","is-referenced-by-count":12,"title":["Aminoglycoside versus carbapenem or piperacillin\/tazobactam treatment for bloodstream infections of urinary source caused by Gram-negative ESBL-producing Enterobacteriaceae"],"prefix":"10.1093","author":[{"given":"Iris","family":"Zohar","sequence":"first","affiliation":[{"name":"Infectious Disease Unit, Wolfson Medical Center, Holon, Israel"},{"name":"Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orna","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Microbiology Laboratory, Wolfson Medical Center, Holon, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orit","family":"Yossepowitch","sequence":"additional","affiliation":[{"name":"Infectious Disease Unit, Wolfson Medical Center, Holon, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley Shapiro Ben","family":"David","sequence":"additional","affiliation":[{"name":"Infectious Disease Unit, Wolfson Medical Center, Holon, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin","family":"Maor","sequence":"additional","affiliation":[{"name":"Infectious Disease Unit, Wolfson Medical Center, Holon, Israel"},{"name":"Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,11,6]]},"reference":[{"key":"2019110607460662600_dkz457-B1","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1086\/524891","article-title":"The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America","volume":"46","author":"Spellberg","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2019110607460662600_dkz457-B2","first-page":"1319","article-title":"Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum \u03b2-lactamase bacteremia","volume":"60","author":"Tamma","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2019110607460662600_dkz457-B3","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/420816","article-title":"Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum \u03b2-lactamases","volume":"39","author":"Paterson","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2019110607460662600_dkz457-B4","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1093\/jac\/dky168","article-title":"Clinical effectiveness of carbapenems versus alternative antibiotics for treating ESBL-producing Enterobacteriaceae bacteraemia: a systematic review and meta-analysis","volume":"73","author":"Son","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2019110607460662600_dkz457-B5","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.ijantimicag.2018.06.018","article-title":"Predictors of outcome in patients with severe sepsis or septic shock due to extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae","volume":"52","author":"Russo","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"2019110607460662600_dkz457-B6","doi-asserted-by":"crossref","first-page":"3747521.","DOI":"10.1155\/2018\/3747521","article-title":"Clinical outcomes of extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae infections with susceptibilities among levofloxacin, cefepime, and carbapenems","volume":"2018","author":"Walker","year":"2018","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"2019110607460662600_dkz457-B7","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/jama.2018.12163","article-title":"Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial","volume":"320","author":"Harris","year":"2018","journal-title":"JAMA"},{"key":"2019110607460662600_dkz457-B8","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/cid\/cir790","article-title":"\u03b2-Lactam\/\u03b2-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum \u03b2-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts","volume":"54","author":"Rodr\u00edguez-Ba\u00f1o","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2019110607460662600_dkz457-B9","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/cid\/cis916","article-title":"Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae: MIC matters","volume":"56","author":"Lee","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2019110607460662600_dkz457-B10","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1086\/380645","article-title":"Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum \u03b2-lactamase: treatment outcome of patients receiving imipenem or ciprofloxacin","volume":"38","author":"Endimiani","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2019110607460662600_dkz457-B11","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/cid\/cix606","article-title":"Empiric therapy with carbapenem-sparing regimens for bloodstream infections due to extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae: results from the INCREMENT cohort","volume":"65","author":"Palacios-Baena","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2019110607460662600_dkz457-B12","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1086\/519268","article-title":"Population-based epidemiologic analysis of acute pyelonephritis","volume":"45","author":"Czaja","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2019110607460662600_dkz457-B13","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1001\/archinte.159.1.53","article-title":"Oral vs intravenous ciprofloxacin in the initial empirical management of severe pyelonephritis or complicated urinary tract infections: a prospective randomized clinical trial","volume":"159","author":"Mombelli","year":"1999","journal-title":"Arch Intern Med"},{"key":"2019110607460662600_dkz457-B14","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/00000441-200610000-00004","article-title":"The clinical impact of bacteremia in complicated acute pyelonephritis","volume":"332","author":"Hsu","year":"2006","journal-title":"Am J Med Sci"},{"key":"2019110607460662600_dkz457-B15","first-page":"50","article-title":"Bacteremia in young urban women admitted with pyelonephritis","volume":"313","author":"Smith","year":"1997","journal-title":"Am J Med Sci"},{"key":"2019110607460662600_dkz457-B16","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/jac\/dkn469","article-title":"Aminoglycoside drugs in clinical practice: an evidence-based approach","volume":"63","author":"Leibovici","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"2019110607460662600_dkz457-B17","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1093\/cid\/ciq257","article-title":"International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases","volume":"52","author":"Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2019110607460662600_dkz457-B18","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.1093\/jac\/dkw296","article-title":"Aminoglycoside-associated acute kidney injury in elderly patients with and without shock","volume":"71","author":"Ong","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2019110607460662600_dkz457-B19","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1177\/106002800303700203","article-title":"Aminoglycoside-associated nephrotoxicity in the elderly","volume":"37","author":"Baciewicz","year":"2003","journal-title":"Ann Pharmacother"},{"key":"2019110607460662600_dkz457-B20","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0002-9343(96)80074-X","article-title":"Comparison of once-daily versus pharmacokinetic dosing of aminoglycosides in elderly patients","volume":"101","author":"Koo","year":"1996","journal-title":"Am J Med"},{"key":"2019110607460662600_dkz457-B21","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/ki.1988.83","article-title":"Aminoglycoside nephrotoxicity","volume":"33","author":"Humes","year":"1988","journal-title":"Kidney Int"},{"key":"2019110607460662600_dkz457-B22","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/jac\/dkm193","article-title":"Efficacy and safety of aminoglycoside monotherapy: systematic review and meta-analysis of randomized controlled trials","volume":"60","author":"Vidal","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"2019110607460662600_dkz457-B23","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"2019110607460662600_dkz457-B24","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/CCM.0b013e31827e83af","article-title":"Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock 2012","volume":"41","author":"Dellinger","year":"2013","journal-title":"Crit Care Med"},{"key":"2019110607460662600_dkz457-B25","doi-asserted-by":"crossref","first-page":"c179","DOI":"10.1159\/000339789","article-title":"KDIGO clinical practice guidelines for acute kidney injury","volume":"120","author":"Khwaja","year":"2012","journal-title":"Nephron Clin Pract"},{"key":"2019110607460662600_dkz457-B26","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0002-9343(86)90489-4","article-title":"Risk factors and comparisons of clinical nephrotoxicity of aminoglycosides","volume":"80","author":"Meyer","year":"1986","journal-title":"Am J Med"},{"key":"2019110607460662600_dkz457-B27","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1128\/AAC.49.2.760-766.2005","article-title":"Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome","volume":"49","author":"Kang","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2019110607460662600_dkz457-B28","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1086\/340616","article-title":"Nosocomial bacteremia caused by antibiotic-resistant gram-negative bacteria in critically ill patients: clinical outcome and length of hospitalization","volume":"34","author":"Blot","year":"2002","journal-title":"Clin Infect Dis"},{"key":"2019110607460662600_dkz457-B29","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1007\/s00134-002-1521-1","article-title":"Extended-spectrum \u03b2-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome","volume":"28","author":"Du","year":"2002","journal-title":"Intensive Care Med"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/advance-article-pdf\/doi\/10.1093\/jac\/dkz457\/30438139\/dkz457.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/advance-article-pdf\/doi\/10.1093\/jac\/dkz457\/30438139\/dkz457.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T17:12:55Z","timestamp":1664644375000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/advance-article\/doi\/10.1093\/jac\/dkz457\/5613763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,6]]},"references-count":29,"URL":"https:\/\/doi.org\/10.1093\/jac\/dkz457","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,6]]},"article-number":"dkz457"}}